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Background: We aimed to identify HBc amino acid differences between subgroups 
of chronic hepatitis B (CHB) patients.  
Methods: Deep sequencing of HBc was performed in samples of 89 CHB patients 
(42 HBeAg positive, 47 HBeAg negative). Amino acid types were compared using 
Sequence Harmony to identify subgroup specific sites between HBeAg-positive and -
negative patients, and between patients with combined response and non-response 
to peginterferon/adefovir combination therapy. 
Results: We identified 54 positions in HBc where the frequency of appearing amino 
acids was significantly different between HBeAg-positive and -negative patients. In 
HBeAg negative patients, 22 positions in HBc were identified which differed between 
patients with treatment response and those with non-response. The fraction non-
consensus sequence on selected positions was significantly higher in HBeAg-
negative patients, and was negatively correlated with HBV DNA and HBsAg levels. 
Conclusions: Sequence Harmony identified a number of amino acid changes 
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Hepatitis B virus (HBV) infection is considered as a major public health issue with an 
estimated 240 million people worldwide being chronically infected. In chronic hepatitis B 
(CHB) patients, the immune systems fails to clear the virus and patients are at increased risk 
for developing liver-related complications such as liver cirrhosis and hepatocellular 
carcinoma (Dienstag, 2008). Two types of drugs are approved for the treatment of CHB 
patients: nucleos(t)ide analogues (NUCs) and pegylated interferon (peg-IFN). Although 
NUCs efficiently block viral replication, treatment rarely leads to a functional cure (defined as 
hepatitis B surface antigen (HBsAg) loss with or without the formation of anti-HBs antibodies) 
(Chevaliez et al., 2013). In CHB patients treated with peg-IFN a functional cure is only 
achieved in 3-7% of patients (Janssen et al., 2005; Marcellin et al., 2004). Improved 
understanding of the replication cycle of HBV resulted in the development of new antiviral 
drugs that directly inhibit viral replication (Durantel and Zoulim, 2016; Tong and Revill, 2016). 
 The HBV core protein (HBc) is a promising antiviral target since it is involved in 
almost all steps of the HBV replication cycle (Summers and Mason, 1982; Tong and Revill, 
2016). HBc consists of an assembly domain (residues 1 to 149), and a C-terminal domain 
(CTD) (residues 150 to 183 or 185, depending on HBV genotype), which are connected by a 
linker region (residues 141 to 149) (Birnbaum and Nassal, 1990; Watts et al., 2002; Yu et al., 
2013; Zlotnick et al., 1997). HBc self-assembles to form viral capsids, predominantly 
consisting of 120 HBc homodimers (Zlotnick et al., 1996), wherein pregenomic RNA (pgRNA) 
is reverse transcribed to relaxed circular DNA (rcDNA). Viral capsids containing rcDNA are 
either encapsulated by the viral envelope proteins and secreted as virions, or they are 
shuttled back to the nucleus where the rcDNA is released and converted to covalently closed 
circular DNA (cccDNA) (Summers and Mason, 1982). The cccDNA is the template for 
transcription of viral mRNAs utilizing host DNA-dependent RNA polymerase. Next to virus 
assembly, HBc is involved in regulation of cccDNA and host-gene expression in the nucleus 
of infected hepatocytes (Guo et al., 2011; Li et al., 2010). 
 HBV replication through an RNA intermediate causes a high mutation rate during 
chronic HBV infection (Akarca and Lok, 1995; Chuang et al., 1993). Mutations in the basal 
core promotor (BCP) and precore (PC) regions are most extensively studied, and abrogate 
the production of hepatitis B e antigen (HBeAg) (Alexopoulou et al., 1997; Buckwold et al., 
1996; Carman et al., 1989; Lok et al., 1994), and were shown to influence peg-IFN based 
treatment response in CHB patients (Erhardt et al., 2000; Jansen et al., 2017; Marrone et al., 
2003; Sonneveld et al., 2012). Previously, it was postulated that mutations in HBc could 
induce secretion of virions containing an immature viral genome, affect envelopment of viral 
capsids, and may evade immune recognition (Akarca and Lok, 1995; Hosono et al., 1995; 
Koschel et al., 2000; Yuan et al., 1999a; Yuan et al., 1999b). However, most previous studies 
analysing HBc mutants used population based sequencing techniques which limits the 
detection of mutations with low frequencies. Importantly, data on the effect of minority 
variants of HBc and their effect on HBeAg status and treatment response are lacking. In our 
cohort of HBeAg-positive and -negative CHB patients treated with a combination of peg-IFN 
and adefovir for 48 weeks, a high rate of HBsAg loss was observed (11-17% at year 2 of 
treatment-free follow-up) (Takkenberg et al., 2013). Here, we studied amino acid differences 
in HBc in our cohort of CHB patients using deep sequencing. We aimed to identify amino 
acids differences in HBc between HBeAg positive and negative patients. Furthermore, we 






MATERIALS AND METHODS 
Study population 
Of the 92 CHB patients who were treated for 48 weeks with peginterferon alfa-2a 180 µg 
subcutaneously once a week, and adefovir dipivoxil 10 mg daily in the initial investigator-
initiated study (controlled-trials.com; ISRCTN 77073364) (Takkenberg et al., 2013), 89 had 
baseline plasma samples available for sequencing analysis. 84/89 patients completed 48 
weeks of treatment and 2 years of follow-up, and comprised the per-protocol population to 
study associations with treatment response (Appendix Figure 1). Achievement of combined 
response (HBeAg negativity, HBV DNA levels ≤ 2,000 IU/mL, persistent normal alanine 




For each patient a pre-treatment (baseline) plasma sample was subjected to 454 ultra-deep 
pyrosequencing. HBV DNA was isolated from 200 µl plasma by the MagNA Pure LC 
instrument, using the Total Nucleic Acid isolation kit (Roche Applied Science). DNA was 
used in a full HBV genome amplification, in an overlapping amplicon approach, using 
degenerative PCR fusion primer sets to cover the HBV genome (Appendix Table 1). For full 
genome coverage, 12 separate overlapping amplicons were generated with an average 
length of 400 nucleotides each (Appendix Table 1). The obtained PCR fragments were 
subjected to deep sequencing using the Roche 454 platform according to the manufacturer’s 
instructions. The entire workflow of PCR and 454 sequencing was performed by 454 Life 
Sciences, Branford CT. First, primer sequences were removed by trimming the first and last 
30 nucleotides of each sequence read followed by removal of low quality nucleotides (phred 
< 28) from the 3’ read end. Subsequently, final read quality was checked using the quality 
control function from QUASR v.7.0.1 (with setting –m 33 and –l 50). Next, all trimmed and 
quality controlled reads were aligned to genotype specific reference sequences (taxonomy 
ID’s: AF297621 (A1), X02763 (A2), D00330 and AB073858 (B), AB033556 (C), X02496 (D), 
X75657 (E)), using the bwasw mapping option of the Burrows Wheeler Aligner (BWA) 
version 0.6.1-r104 with default settings. From the resulting sequencing alignment map (SAM) 
file coverage overviews per reference sequence position were generated disregarding 
nucleotides with a phred score below 30. Amino acid variation per position was determined 
disregarding codons containing >1 nucleotide with a phred < 20.  
 
Multiple sequence alignment for Sequence Harmony 
Aligned reads were collected for the 84 patients. Nucleotide sequences were translated and 
summarized as frequency counts per amino acid type per position per patient. A multiple 
sequence alignment between patients was performed based on consensus sequences per 
patient using the Praline multiple sequence analysis tool with global pre-profiling and default 
settings (Pirovano et al., 2008; Simossis et al., 2005). This multiple alignment of the 
consensus sequences was used to align frequency count tables between patients. 
 
Comparison of viral sequences with Sequence Harmony 
The Multi-Harmony (SHMR) webserver (www.ibi.vu.nl/programs/shmrwww) was used to 
calculate Sequence Harmony (SH) scores (Brandt et al., 2010; Pirovano et al., 2006), to 




on the aligned frequency count tables. The SH algorithm is an entropy-based method, which 
measures the overlap in distribution of amino acid types between subgroups at positions 
within an alignment of related protein sequences divided into groups. An SH score of 0 
indicates amino acid positions that are specific for one of the sequence groups, whereas an 
SH score of 1 indicates a complete overlap at this amino acid position between the two 
groups. For two subgroups (A and B), SH measures the overlap in distribution of amino acid 
types (x) at a certain position (i) in the sequence alignment using a formula based on relative 
entropy (mutual information) as follows: 
SH𝑖










𝐴 indicates the observed frequency in group A for amino acid type x at position i in the 
sequence, and 𝑝i,x
𝐵 analogously for group B.  
In our dataset, the observed frequencies p are not counted from the alignments of each 
group, as is done in the original method, but derived from the frequency per patient 
determined by next generation sequencing, as described above. Each patient will therefore 
have the same weight in (or impact on) the total score in each group independent of the 
number of sequence reads. Sequence coverage of the core protein is shown in Appendix 
Figure 2. To exclude spurious variations, e.g. arising from sequencing errors, we discounted 
all variants with a support of less than 50 reads. Most positions have a coverage of at least 
5000 (Appendix Figure 2), which means that for a typical site, a minimum support of about 
1% is effectively required. In addition, an empirical Z-score is calculated, reflecting the 
significance of the SH score obtained based on 100 random shuffling events of the 
sequences between the two groups. Cut-off scores for selecting positions significant for 
functional differences between the groups analysed, were set as SH < 0.960 and Z-score < -
0.8. The high SH cut-off allows for detection of relatively small differences (>4%) against a 
background of overall high conservation. The Z-scores display the accuracy of a given result; 
the more negative the Z-score the less likely it is that the results arose by chance. For each 
HBV genotype, we compared HBeAg positive patients with HBeAg negative patients. 
Furthermore, we compared HBeAg positive and negative patients with a combined response 
(CR) to antiviral treatment to those who did not respond to treatment. 
 
Amino acid variation in HBc 
SH yielded a list of amino acid differences at selected positions in HBc between HBeAg 
positive and negative individuals, and a corresponding list for HBeAg negative individuals 
with and without treatment response. As per position these differences were relatively minor, 
we assessed the explanatory power of the SH selected positions combined. For this, we 
analyzed the amino acid variation at the SH selected positions in each group. For 
comparison of the amino acid variation at SH selected positions between HBeAg-negative 
and HBeAg-positive patients, the consensus amino acid sequence of HBeAg-positive 
patients was used as a reference to calculate the fraction of non-consensus sequence (% 
amino acid variation at that position). Similarly, for comparison of the amino acid variation at 
SH selected positions between responders and non-responders, the consensus amino acid 
sequence of non-responders was used as a reference. The average amino acid variation for 
the set of SH selected positions per patient was used to analyze the variation in HBc 







Analysis of the protein three-dimensional structure informs us on the relative locations of the 
selected positions. Proximity in the structure indicates a possible shared functional role of the 
selected positions. We took the 3J2V X-ray cryo-EM structure of the HBc (Yu et al., 2013). 
This structure contains 4 copies of HBc in its assembled capsid conformation. The C-terminal 
region comprising residues 150 to 183 or 185 was not resolved. The sites selected by the SH 
analysis, i.e., the residues scoring below the SH and Z-score cut-offs, for HBeAg positive 
versus negative, and for HBeAg negative treatment response versus no response as 
described above, were mapped onto the three-dimensional structure. The mapped positions 
were clustered based closest distance between side-chain atoms (or the Cα for glycine); we 
used cut-off of 6.0Å, 7.0 Å and 8.0 Å. As we specifically analyze the residue side chains for 
the clustering, we also consider sequentially adjacent (consecutive) amino acids whose 
sidechains are within the cutoff as clusters. Mapped positions and clusters were visualized 
using PyMol (The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC). 
 
Statistical analyses 
We tested for differences in amino acid variation between study groups using the Mann-
Whitney U test, and correlations were analysed with Spearman’s correlation coefficient (R) 





Characteristics of CHB patients with 454 deep sequencing data available (n=89) are shown 
in Table 1. Patients were HBeAg positive (n=42) or HBeAg negative (n=47), and had HBV 
genotypes A (n=28), B (n=15), C (n=12), D (n=25), or E (n=9). Eighty-four patients completed 
treatment and follow-up and comprised the per-protocol population used for studying 
associations with treatment response. At week 72, 14/42 (35%) of HBeAg positive and 16/47 
(36%) of HBeAg negative patients had combined response. HBsAg loss at 2 years of follow-
up (week 144) was achieved in 5/42 (13%) of HBeAg positive and 8/47 (18%) of HBeAg 
negative patients (Jansen et al., 2014).  
 
Sequence Harmony identifies viral variants in precore and HBc that correlate with HBeAg 
status 
The SH method was used to identify amino acid differences in HBc between HBeAg positive 
and HBeAg negative patients with HBV genotypes A, B, C and D. HBV genotype E was 
excluded for this analysis since the number of HBeAg positive patients was too low (fewer 
than three patients). A low SH score indicates a position where the amino acid composition is 
different between the two study groups. In addition, an empirical Z-score is calculated based 
on 100-fold random permutation, to reflect the significance of the SH score (see Methods for 
details). The SH analysis yielded 54 sites with a SH score below the defined cut-off values (< 
0.960), and a support of at least 50 read (corresponding to about 1% coverage, see 
Appendix Figure 2), indicating differences in amino acids present at these sites between the 
HBeAg positive and negative groups. These selected sites all have high (negative) Z-scores 
(< -0.8) (Appendix Table 2), indicating that the minimum number of reads required of 50 




our data for HBc was about 5000 (Appendix Figure 2), this allows the confident 
identification of minor variants of about 1%. Most of the observed amino acid differences 
between HBeAg positive and negative patients are present in minor viral populations. This is 
reflected in the relatively high median SH score for HBeAg status of 0.886 (IQR: 0.783 – 
0.925) (Figure 3), and that most of the differences in amino acid composition are present as 
minor viral variants (lowercase letters), while the major variants (uppercase letters) are often 
similar between both groups (Appendix Table 2). Of the 54 positions that were identified by 
SH analysis, 23 positions were present in more than one HBV genotype. In the precore 
region, the amino acid composition was different between HBeAg positive and negative 
patients in the majority of HBV genotypes for residues at precore position 28 (genotypes A, 
B, D) and position 29 (genotypes A, C, D) (Table 2). HBc region residues 49 (genotypes A, 
B, C, D), 77 (genotype A, B, C) and 130 (genotype A, B, D) had a different amino acid 
composition between HBeAg positive and negative patients in the majority of HBV genotypes 
(Table 2).  
 
Sequence Harmony identifies viral variants in HBc that correlate with therapy response 
Most of the observed amino acid differences between combined responders and non-
responders were present as minor viral variants, with a median SH score of 0.809 (IQR: 
0.689 – 0.849) (Appendix Figure 3), which indicates a relatively high similarity between the 
groups. First, we studied the amino acid differences in HBc in HBeAg positive patients with 
and without response to antiviral treatment. This analysis focused on HBV genotypes A and 
C, since the number of HBeAg positive responders was too low for HBV genotypes B, D and 
E. The SH analysis yielded 7 positions with differences in amino acids between HBeAg 
positive responders and non-responders (SH score < 0.960, Z-score < -0.8, and support ≥50 
reads) (Appendix Table 3). There was no overlap in the identified positions for HBV 
genotype A and C.  
To identify amino acid differences in HBeAg negative responders versus non-
responders, we have calculated SH scores for patients with HBV genotypes A, D and E. 
Patients with HBV genotypes B and C could not be assessed since the number of HBeAg 
negative responders was too low. The SH analysis yielded 22 sites with a different amino 
acid composition between HBeAg negative responders and non-responders (SH score < 
0.960, Z-score < -0.8, and support ≥50 reads) (Appendix Table 3). Of these 22 positions, 
only three positions were present in more than one HBV genotype (HBc residues 49, 80 and 
114).  
 
Structural mapping of the Sequence Harmony results reveals clustering of amino acids 
To better understand the meaning of the SH results, we mapped the positions that differed 
significantly between study groups onto the three-dimensional structure of HBc. The 3J2V 
cryo-EM structure contains four chains in the unit cell, providing a detailed view of the HBc 
structure as well as most interactions that occur within the assembled icosahedral capsid. 
This allows us to analyse in detail the 24 SH selected residues per chain from the 
comparison between HBeAg negative and positive patients (HBV genotypes A and D); note 
that this is fewer than the 54 listed in Appendix Table 2, as there also positions for the other 
genotypes are included, and the available crystal structure does not include the pre-core 
domain, nor the C-terminal domain from position 147 onwards.  
Figure 1A+B show these 24 selected sites, several of which show distinct clusters in the 




capsid (shown in red and purple in Figure 1C+D) and some at the interfaces between the 
HBc capsid protein monomers (shown in red in Figure 1A+B). Around the four-helical bundle 
on the A-B interface, from top to bottom (Figure 1A+B), we find the largest clusters. At a 
clustering cut-off of 6.0 Å (see Methods for details) for genotype A, selected positions 59 and 
60 form a cluster near the center within each monomer chain, and positions 9, 49, 50, and 
113-114 do likewise near the bottom (Figure 1B+D). In between those intra-chain clusters, 
positions 5 and 60 from chains A and B form a 5-residue inter-chain cluster (5A, 59B, 60B, 
63B, 67B). At 7.0 Å, these merge into two big clusters (5A, 9A, 49A, 50A, 59B, 60B, 63B, 
67B, 105B, and vice versa for B and A), also encompassing position 105. Other sites mainly 
cluster in twos or threes (at 6.0 Å): 130-131, and 21, 24 (at the left in chain A). One other 
inter-chain cluster for genotype A is noteworthy, albeit only at a cut-off of 8.0 Å: sites 40 and 
45 between chains B and D (Figure 1B+D). The selected positions for genotype D also add 
an inter-chain cluster at 8.0 Å: sites 12 and 40 between chains C and B.  
For the comparison of HBeAg negative patients (HBV genotype A and D) with combined 
response versus non-response (shown in blue and purple in Figure 1C+D, and in blue in 
Figure 1E+F), observed differences were smaller, and the subsequently smaller set of 
selected residues also leads to fewer clusters, most of which are close together in the 
sequence and within the chain. For the genotype A selection, we only find a pair of residues 
clustering at a cut-off of 8.0 Å: 114 and 116. For genotype D at 6.0 Å, two clusters are 
obtained: 66 and 69, and positions 78, 79, and 80 of both chains A and D. 
Clustering of SH selected residues from the comparison between HBeAg negative and 
positive patients for HBV genotype B and C are shown in Appendix Table 4. 
 
Higher amino acid variation in HBc in HBeAg negative patients compared to HBeAg positive 
patients 
Based on the positions revealed by the SH analysis (Appendix Table 2), we calculated the 
amino acid variation (the fraction non-consensus sequence on selected positions) for HBeAg 
negative patients compared to the reference sequence of HBeAg positive patients. As a 
control, the amino acid variation for the HBeAg positive patients was calculated compared to 
its own reference sequence. The median amino acid variation of patients with various HBV 
genotypes was significantly higher for HBeAg negative patients versus HBeAg positive 
patients (Figure 2A). The presence of mutations in the BCP region, A1762T and G1764A, 
have been associated with HBeAg negative status (Alexopoulou et al., 1997; Buckwold et al., 
1996). Mutations in BCP region of patients included in this analysis have previously been 
described (Jansen et al., 2017). Multivariable regression analysis showed that the 
association between the higher amino acid variation and an HBeAg negative status was 
independent of the presence of BCP mutations and HBV genotype (Table 3).  
For comparison, we calculated the amino acid variation for the rest of HBc (entire HBc 
without positions included in the SH score). A significant correlation was found between the 
amino acid variation based on the SH selection and the rest of HBc (Spearman’s R=0.3961, 
P=0.0005), independent of HBV genotype (Figure 2B, Appendix Figure 4). The SH based 
amino acid variation for HBeAg status had a significant negative correlation with both pre-
treatment HBV DNA level (Spearman’s R= -0.7039, P<0.0001), HBsAg-level (Spearman’s 
R= -0.5457, P<0.0001) (Figure 2C+2D), and ALT level (Spearman’s R= -0.2664, P=0.0218).  
The amino acid variation in HBc of patients with various HBV genotypes based on the SH 
results was not significantly different between HBeAg negative non-responders and 








This was the first study analysing amino acid differences of HBc in subgroups of CHB 
patients using deep sequencing and the SH algorithm. Differences in amino acid composition 
of HBc between HBeAg positive and negative patients were mostly found at the inner surface 
of the viral capsid and the intra-dimer interface, while most amino acid differences between 
HBeAg negative non-responders and responders were mainly located at the outer surface of 
the viral capsid. The amino acid variation as determined by the fraction non-consensus 
sequence on SH-selected positions, was higher in HBeAg negative patients, and was 
negatively correlated with HBV DNA levels and HBsAg levels. 
 The SH algorithm offers an way to quantify the overlap in amino acids between study 
groups (Brandt et al., 2010; Pirovano et al., 2008), which avoids personal biases that may 
arise when manually inspecting such alignments, and the a-priori bias on conserved 
positions that is applied by most other methods for detecting group-specific positions. The 
SH algorithm thus enables us to identify positions that may explain differences in disease 
outcome between patients. We observed a different amino acid composition between HBeAg 
positive and HBeAg negative CHB patients at PC residue 28, confirming a well-established 
point mutation from G to A at position 1896 of the PC region. This mutation converts the 
TGG codon for tryptophan to TAG, a translational stop codon, and thereby prevents the 
production of HBeAg which plays a role in suppressing immune response to HBV infection 
(Buckwold et al., 1996; Carman et al., 1989; Chen et al., 2004; Lok et al., 1994; Milich et al., 
1990). Furthermore, we confirmed previous findings that sequence diversity in HBc is greater 
in HBeAg negative patients than HBeAg positive patients (Akarca and Lok, 1995; Chuang et 
al., 1993; Homs et al., 2014). (Akarca and Lok, 1995; Chuang et al., 1993; Homs et al., 
2014). Although HBc and HBeAg are encoded by the same ORF, these proteins have a 
distinct structure and function (Zlotnick et al., 2013). While HBc proteins assemble into core 
particles encapsidising the viral RNA genome, the HBeAg protein contains a signal peptide 
and is secreted after processing. Mutations in the core gene ORF will result in amino acid 
changes affecting both HBc and HBeAg. In HBeAg negative patients, who have a viral 
variant expressing no or reduced amounts of HBeAg (Alexopoulou et al., 1997; Buckwold et 
al., 1996; Carman et al., 1989; Lok et al., 1994), amino acid changes in the core ORF will 
only affect the core protein. We observed that amino acid changes in HBc of HBeAg-
negative patients were mostly found at the inner surface of the viral capsid. This suggest that 
the high selection pressure to conserve the amino acids at these positions is lost in HBeAg 
negative patients, most likely because these positions are essential to maintain HBeAg 
structure and function in HBeAg-positive patients. It is also possible that structures at the 
inner face of the core protein may be on the surface of the HBeAg (Zlotnick et al., 2013), 
therefore the HBeAg specific immune response may also play a role in the conservation of 
these residues in HBeAg positive patients.  Furthermore, core mutations in HBeAg-negative 
patients could also lead to optimization of the HBc structure. We observed that differences in 
amino acid compositions associated with HBeAg status were found in both the assembly 
domain (in 39/149 residues, 26%), and in the CTD (in 9/34 residues, 26%) of HBc. Albeit the 
arginine-rich CTD is not necessary for the assembly of viral capsids (Lewellyn and Loeb, 
2011; Nassal, 1992a), it has essential functions in the HBV replication cycle such as binding 




import (Gazina et al., 2000; Kann and Gerlich, 1994; Lewellyn and Loeb, 2011; Liao and Ou, 
1995; Nassal, 1992a; Petit and Pillot, 1985; Yeh and Ou, 1991). In line with previous studies, 
we found few variance in the arginine rich part of the CTD that is important for DNA binding, 
while we did observe minor amino acid variation in the arginine residues of the CTD involved 
in encapsidation of RNA (residues 150-154) in HBeAg negative patients (Akarca and Lok, 
1995; Hatton et al., 1992). No amino acid variations were observed in the CTD serine (S) 
phosphorylation sites that are required for reverse transcription (S157, S164, and S170) 
(Gazina et al., 2000). In HBeAg negative patients, we did observe variation in an additional 
phosphoacceptor site with replacement of serine by threonine at residue 178 (Jung et al., 
2014). 
 The structure of HBc is dominated by an α-helical hairpin (Wynne et al., 1999). The 
base of the protein is formed by a hydrophobic core which stabilizes the monomer fold, 
consisting of residues 6, 9, 15-16, 18-19, 23-24, 102-103, 110, 115, 118-119, 122, 125, and 
140 (Wynne et al., 1999). Our study confirms that these hydrophobic residues are highly 
conserved (Wynne et al., 1999), with no evidence of coexistence of hydrophilic residues. 
However, we did observe amino acid differences in other residues at the base of the α-helix, 
such as leucine 60 (L60), that was previously shown to support intracellular capsid formation 
but abrogate virion secretion (Ponsel and Bruss, 2003). HBc dimers, required for the 
formation of the capsid, associate via their α-helical hairpins to form a four-helix bundle 
(Wynne et al., 1999). A disulphide bridge at the dimer-interface between the cysteine 61 
(C61) residues stabilizes its association (Nassal, 1992b; Selzer et al., 2014). We did not 
observe differences in viral sequences between subgroups in the C61 position. Also, no 
relevant variations were observed in other residues which are known to be important for 
inter-subunit packaging such as arginine 127 (A127), proline 129 (P129), tyrosine 132 
(Y132), and I139 (Wynne et al., 1999). 
Previously, it was shown that replacement of phenylalanine/isoleucine (depending on 
HBV genotype) by leucine at residue 97 (FI/97L) resulted in secretion of virions containing 
immature (replication intermediate) single stranded (ss) DNA (Le Pogam and Shih, 2002; 
Yuan et al., 1999a). It was proposed that this immature virion secretion can be offset by 
another frequently occurring mutation; proline to threonine at position 130 (P130T) (Yuan 
and Shih, 2000). In our study, the dominant residue at position 97 was an isoleucine in HBV 
genotype B and C HBeAg positive patients, whereas this was an isoleucine, valine or leucine 
in HBeAg negative patients. Interestingly, we did not observe a viral population with a 
threonine at position 130 in HBeAg negative patients with genotypes B or C, suggesting that 
the FI/97L mutation is not always rescued by a second mutation in vivo. Mutations P5T and 
L60V, associated with inhibition of virion secretion possibly by interference with capsid 
envelopment (Le Pogam et al., 2000), were present as minor viral population in both HBeAg 
negative as HBeAg positive patients.  
 The presence of BCP and/or PC variants, as dominant or as minor population, was 
previously shown to limit the response to peg-IFN or NUC monotherapy in CHB patients 
(Bayliss et al., 2016; Erhardt et al., 2000; Jansen et al., 2017; Marrone et al., 2003; 
Sonneveld et al., 2012). In addition, our study demonstrates differences in several residue 
positions in HBc between HBeAg negative non-responders and combined responders to 
treatment with peg-IFN and NUCs. Interestingly, a substantial part of these residues were 
located at the outer surface of the viral capsid (residues 77-80), where the major 
immunodominant region of HBc has been mapped (Pumpens and Grens, 2001; Salfeld et al., 




that binds to HBsAg, the inner surface of the envelop, which is essential for virus assembly 
(Bottcher et al., 1998; Dyson and Murray, 1995). HBV capsids are highly immunogenic, and 
are able to elicit B cell, T helper cell, and cytotoxic T cell responses. Therefore, amino acid 
substitutions in HBc may alter immune recognition and thereby affect immune clearance and 
treatment outcome (Akarca and Lok, 1995; Radecke et al., 2000). So far, a large number of 
HBV specific epitopes has been described (Desmond et al., 2008). The HBc 18-27 epitope 
(FLPSDFFPSV), evoking both CD4+ and CD8+ T cell responses, has been characterized 
extensively (Bertoletti et al., 1993; Bertoletti et al., 1997; Bertoni et al., 1997; Desmond et al., 
2008; Hosono et al., 1995; Kefalakes et al., 2015; Lee et al., 1997; Nayersina et al., 1993; 
Rehermann et al., 1995a; Rehermann et al., 1995b). In this study, we observed several 
amino acid changes in this epitope, including one of the anchor residues, which were 
associated with both HBeAg status (V27T/I in HBeAg negative patients) and treatment 
response in HBeAg negative patients (V27A in responders). We were unable to analyse 
amino acid differences of HBc in patients with and without HBsAg loss, due to the limited 
number of patients with HBsAg loss in the study group. 
 HBeAg status has previously been associated with several markers of viral 
replication: HBeAg negative patients have lower HBsAg and HBV DNA levels in plasma and 
a higher viral diversity (Fattovich et al., 2008; Lim et al., 2007; Takkenberg et al., 2013; van 
de Klundert et al., 2012). In agreement, the amino acid variations at SH selected positions 
identified based on HBeAg status, were inversely correlated with HBV DNA and HBsAg 
levels. A greater variability in the HBc region in HBeAg negative patients than in HBeAg 
positive patients quasispecies was observed previously in a small number of CHB patients 
using deep sequencing techniques (Homs et al., 2014). It was postulated that an increased 
viral diversity may be associated with HBeAg seroconversion (Akarca and Lok, 1995; Homs 
et al., 2014), however in our analysis we did not take the time delay between HBeAg 
seroconversion and time of sequencing into account.  
A strength of our study is that we have used samples of a well-characterized cohort of 
CHB patients including both HBeAg negative and positive patients. Furthermore, we have 
used deep sequencing techniques enabling to identify minority viral variants that may have 
been missed in earlier studies using population sequencing methods.  
Based on this data, our analysis offers a better understanding of the possible drivers of 
HBc evolution in different subgroups of CHB patients. Amino acid variations in HBc may 
affect virion secretion, reverse transcription, or change important immunogenic regions of 
HBc. The two alternative fates of HBV cores, either envelopment followed by secretion, or 
transport to the host cell nucleus for release of rcDNA, require careful regulation of their 
stability (Cui et al., 2015). Finally, in the context of development of new antivirals for HBV, of 
which HBc allosteric modulators are promising candidates (Durantel and Zoulim, 2016; 
Klumpp et al., 2015; Yang et al., 2016), it is essential to gain better insight in the different 
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Table 1: Baseline characteristics. Variables are shown for patients included in the present 
study with 454 DS data available (N=89) according to HBeAg status 
 






Demographics   
Female, n (%) 8 (19) 15 (32) 
Mean age, years (SD) 35.76 (9.45) 43.07 (9.84) 
Ethnicity   
  Caucasian, n (%) 16 (38) 12 (26) 
  Asian, n (%) 19 (45) 14 (30) 
  African, n (%) 7 (17) 21 (45) 
IFN naïve, n (%) 33 (79) 33 (70) 
Laboratory characteristics   
Median ALT, U/L (IQR) 97 (50-215) 63 (47-118) 
HBV genotype   
  A, n (%) 17 (40) 11 (23) 
  B, n (%) 8 (19) 7 (15) 
  C, n (%) 7 (17) 5 (11) 
  D, n (%) 8 (19) 17 (36) 
  E, n (%) 2 (5) 7 (15) 
Mean HBV DNA, log10 IU/mL (SD) 8.02 (1.23) 5.56 (1.08) 
Mean HBsAg, log10 IU/mL (SD) 4.29 (0.74) 3.33 (0.67) 
Mean HBeAg, log10 IU/mL (SD) 2.61 (1.03) n.a. 
Treatment response 
a   
Combined response at week 72, n (%) 14 (35) 16 (36) 
HBsAg loss at week 144, n (%) 5 (13) 8 (18) 
 
n.a.: not applicable; a. Therapy response was determined in the per-protocol population (n=84) excluding 2 HBeAg-positive and 




Table 2:  Amino acid differences between HBeAg positive and negative patients occurring in 
majority of HBV genotypes 
 
Residue HBV GT SH-score Z-score HBeAg pos a HBeAg neg a 
Precore 
b      
28 A 0.869 -1.960 W(*) W* 
“ B 0.548 -10.593 W* *w 
“ D 0.241 -15.815 W* *(w) 
29 A 0.861 -2.382 G(d) Gd 
“ C 0.747 -1.400 Gs(d) DGns 
“ D 0.785 -7.915 Gd GD 
Core 
c      
49 A 0.934 -1.585 S St 
“ B 0.743 -2.045 S TS 
“ C 0.689 -2.027 S ST 
“ D 0.896 -1.652 S St 
77 A 0.520 -6.940 Eq Qde(n) 
“ B 0.874 -1.387 E Ed 
“ C 0.451 -3.562 E DEQ 
130 A 0.941 -1.265 P(l) Pq 
“ B 0.911 -1.878 P Pa 
“ D 0.835 -0.894 P(s) Plq(s) 
 
Sequence Harmony (SH) score < 0.960 and Z-score < - 0.8;  
a. Summary of amino acid type frequencies in the indicated groups, sorted starting from the most frequently occurring type, 
lower case letters are used for a frequency less than half of the most occurring, and between brackets for a frequency of less 
than 1%; *: stopcodon; 
b. Numbering from start of precore in genotype A reference sequence;  
c. Numbering from start of core in genotype A reference sequence. 
 
 
Table 3. Multivariable regression analysis of amino acid variation in subgroups of chronic 
hepatitis B patients 
 Variable B
a
 p-value 95%  CI 
HBeAg status 
 
Amino acid variation at 
SH-selected positions 
3,56 0,001 1,51 – 5,62 
 BCP-mutations
b 
0,192 0,001 0,084 – 0,299 
 HBV-genotype 0,069 ns -0,009 – 0,147 
Treatment response in HBeAg-negative 
 
Amino acid variation at 
SH-selected positions 
0,297 ns -3,3 – 3,9 
 HBV-genotype -0,027 ns -0,15 – 0,09 
a. Unstandardized coefficient (B) indicates the difference in the outcome (HBeAg status or treatment response in HBeAg-
















Fig 1. Structural mapping of SH selected sites, onto the four chains contained in the 3J2V HBV core protein crystal structure. The structure is arranged as 
two dimers: a dimer of A with B, and of C with D, which are connected by interactions between chains B and C. Both dimers (A-B and C-D) are two-fold 
rotation symmetric around the ‘top-bottom’ axis, which is perpendicular the capsid surface. We show the protein in two representations: cartoon (panel 
A+B+D+E) and surface (panel C+D); and in two orientations: side, i.e. tangential to the capsid surface, with the A-B dimer two-fold rotational symmetry axis 
pointing up (left-hand column), and inside, i.e. looking out from the capsid interior outwards, with the A-B axis pointing away from the viewer (right-hand 
column). Because of the symmetry, the visible side of chain A corresponds to opposite (back) side of chain B. And because both A-B and C-D dimers are 
largely identical, we show mainly chains A and B, and the interactions from B to C. In the cartoon representation, selected sites also drawn as sticks. 
Selected sites labelled by their single letter amino acid and reference position. Chains are labelled and indicated by different pastel shades in the surface 
representation. (1A+1B) 24 selected sites for HBeAg positive versus negative patients (HBV genotype A and D) are shown in red; (1C+1D) Both selections 
(HBeAg status and treatment response) are shown; sites selected by both analyses are indicated in purple; (1E+1F) 11 selected sites for HBeAg negative 




Fig 2. (2A) Amino acid variation based on Sequence Harmony (SH) selection is higher in HBeAg negative patients (white dots) compared to HBeAg positive 
patients (black dots). Median and interquartile range (IQR) are shown. Mann-Whitney U test was used to compare study groups, **** p < 0.0001. (2B) HBeAg 
negative patients have a higher amino acid variation in both SH selection and rest of HBV core protein compared to HBeAg positive patients. There was a 
significant correlation between SH based amino acid variation and rest of HBV core protein in HBeAg negative patients. Significant correlation between SH 
based amino acid variation and HBV DNA level (2C) and HBsAg level (2D). Spearman’s Rank test for correlation was used. 
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Fig 3. No significant difference in median Sequence Harmony based amino acid variation between HBeAg negative non-responders and responders to 
antiviral therapy. Median and interquartile range (IQR) are shown. Mann-Whitney U test was used to compare study groups. 
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